Status:

NOT_YET_RECRUITING

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Lead Sponsor:

University of Virginia

Collaborating Sponsors:

University of Michigan

Medical University of South Carolina

Conditions:

Status Epilepticus

Eligibility:

All Genders

1+ years

Phase:

PHASE3

Brief Summary

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.

Detailed Description

KESETT is a multicenter, randomized, blinded study to determine whether adding 1 mg/kg or 3 mg/kg dose of KET to 60 mg/kg LEV can terminate status epilepticus (SE) in a larger fraction of subjects wit...

Eligibility Criteria

Inclusion

  • The patient was witnessed to have a convulsive seizure for greater than 5-minute duration
  • The patient received an adequate dose of benzodiazepines. The doses may be divided.
  • The last dose of a benzodiazepine was administered 5-30 minutes before study drug administration.
  • Continued or recurring seizures in the Emergency Department.
  • Age 1 years or older
  • Known or estimated weight ≥10 Kg

Exclusion

  • Known pregnancy
  • Prisoner
  • Opt-out identification or otherwise known to be previously enrolled in KESETT
  • Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital, or other agents defined in the MoP) for this episode of SE
  • Treatment with sedatives with anticonvulsant properties other than benzodiazepines for this episode of SE(propofol, etomidate, ketamine or other agents defined in the MoP)
  • Endotracheal intubation prior to enrollment
  • Acute traumatic brain injury clearly precedes seizures
  • Scalp injury or burn preventing EEG placement
  • Known allergy or other known contraindication to KET or LEV
  • Hypoglycemia \< 50 mg/dL
  • Hyperglycemia \> 400 mg/dL
  • Cardiac arrest / post-anoxic seizures

Key Trial Info

Start Date :

August 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2029

Estimated Enrollment :

770 Patients enrolled

Trial Details

Trial ID

NCT06907173

Start Date

August 1 2025

End Date

December 1 2029

Last Update

April 2 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.